2. Management and Key Leader Group

Management and Key Leader Group

Introducing Management and
Key Leader Group of Helixmith.

개인정보처리방침

닫기

이메일무단수집거부

닫기

사이트맵

ABOUT US
BUSINESS
GROUP
IR
PR
CAREERS
닫기

Sunyoung KIM, D. Phil
CEO, Representative Director

  • 1996~present

    CEO of Helixmith

  • 2014~2016

    Director of National Research Council of Science & Technology (NST)

  • 2013~2015

    President of Seoul National University Bio-MAX Institute

  • 2010~2011

    Investment manager in fusion new industry sector of R&D strategy planning group, ministry of knowledge economy

  • 2006~2008

    The 1st and 2nd Chairman of the Korean Society of Gene Therapy

  • 1992~2018

    Professor, Biological Sciences, Seoul National University

  • 1990~1992

    Assistant Professor, Harvard Medical School

  • 1987~1989

    Postdoctoral fellowship, MIT Whitehead Institute

  • 1986

    PhD, Molecular Genetics, the University of Oxford

  • 1984

    Master, Microbiology/Molecular Genetics, Harvard University

  • 1982

    Master, Bioengineering, MIT

  • 1978

    BS, Microbiology, Seoul National University

Sunyoung KIM D. Phil

Seungshin Yu, Ph.D.
CTO, Representative Director

  • 2020~present

    CTO of Helixmith

  • 2008~2019

    Former Director of Bio Headquarter, President of Research Institute

  • 2005~2008

    Department Head, Takara Bio Research Institute

  • 1995~1997

    Postdoctoral fellowship, MIT Whitehead Institute

  • 1984~1995

    BS, Microbiology, Seoul National University, Master/Ph.D, Virology at Seoul National University

Seungshin Yu CTO

Sinyoung KIM
COO, Representative Director

  • 2021~present

    COO of Helixmith

  • 2010~2020

    CEO/Vice Chairman, Sejong Telecom Incorporated

  • 2007~2010

    CEO, Boas International Capital

  • 2005~2007

    CEO, Solomon Capital

  • 2003~2005

    CEO, Zionex Inc

  • 1999~2002

    Executive Director, Goldman Sachs Inc.

  • 1998~1999

    Vice President, Lone Star Funds

  • 1996~1998

    Director, Dongah Group

  • 1983~1996

    Planning Office, Samsung C&T Corp., Secretary’s Office, Samsung Group

  • 1984

    BS, Economics, Yonsei University

Sinyoung KIM COO

Key Leader Group

  • Process Development & Manufacturing TechnologiesKyungdong Bae

  • Clinical DevelopmentYoungjoo Park

  • Phytotherapeutics, R&DDoo suk Lee

  • Corporate DevelopmentJehee Suh

  • Head of Financial Administration, Executive DirectorSOONMOON JANG

  • Clinical DevelopmentWilliam K. Schmidt

  • Clinical OperationsAdam Ruskin

  • Head of MedicalWilliam O. Frank

  • Regulatory AffairsCindy Fisher

  • Quality AssuranceJose Zapata

Key Leader Group

Process Development & Manufacturing TechnologiesKyungdong Bae

  • Director & Co-chairman, Korean Society for Biotechnology and Bioengineering
  • Member of Expert Committee at Advanced Therapy and Expert Panel at Plasmid DNA, US Pharmacopeia (2020~2025 cycle)
  • Director & Head of Vaccine Process and Analytical Development, Janssen Vaccine Korea
  • Adjunct professor, Department of Bioengineering, Graduate School of Inha University
  • BS/MA/PhD, Department of Chemical and Biological Engineering, Inha University

Key Leader Group

Clinical DevelopmentYoungjoo Park

  • Senior Director for External Cooperation and Business Development, Korea National Enterprise for Clinical Trials, Affiliation of Ministry of Health and Welfare
  • Sanofi, Head of Clinical Study Unit, R&D
  • MSD, Senior Manager for biostatistics, data management, pharmacovigilance, and medical writing
  • Master of Public Health, Ph.D. in Epidemiology, Seoul National University
  • BS, Life Science, Ewha Womans University

Key Leader Group

Phytotherapeutics, R&DDoo suk Lee

  • Nature Korean Medicine Clinic
  • Korean Medical License (Ministry of Health and Welfare)
  • Ph.D., Department of Biological Sciences, Seoul National University
  • BS, Department of Korean Medicine, College of Korean Medicine, Dongguk University

Key Leader Group

Corporate DevelopmentJehee Suh

  • CAR-T cell therapy subsidiary of Helixmith
  • Former Head of Global Business Strategy and Business Development
  • Partner at McKinsey & Company (Pharmaceuticals & Medical Products)
  • Marketing, Novartis Korea
  • Wharton MBA, major in Healthcare Management
  • BS, Biology, Seoul National University

Key Leader Group

Head of Financial Administration, Executive DirectorSOONMOON JANG

  • Executive director: Ansell Korea, DentsplySirona Korea, PharmaLink Korea, Quintiles Transnational Korea
  • Head of Cap Gemini Ernst&Young Korea
  • Manager of Sandvik Korea, Hanglas
  • AICPA certificate
  • BS, Department of accounting, Sungkyunkwan University

Key Leader Group

Clinical DevelopmentWilliam K.Schmidt

  • President, North Star Consulting
  • Chief Medical Officer, Ensysce Bioscience
  • Vice President of Clinical Development, EicOsis
  • Postdoctoral training, Boston University School of Medicine
  • PhD in Pharmacology, UC San Francisco

Key Leader Group

Clinical OperationsAdam Ruskin

  • Sr. Contractor (Clinical Operations), ApprovedCRO
  • Head (Clinical Development), Asuragen
  • VP (Clinical Operations), LabCRO, Inc.
  • Sr. Director (Clinical Operations), Genturadx
  • Sr. Director (Clinical Operations), Emergent BioSolutions
  • Director (Clinical Operations), Emergent BioSolutions Inc Sr. Director (Clinical Research and Operations), Maxygen
  • Director (Clinical Operations), Cerexa
  • Principal Program Manager, PPD
  • Department Lead (Clinical Operations, Biostatistics and Data Management), Natus Medical
  • Director (Clinical Operations), Ischemia Research and Education Foundation
  • Epidemiologist, Fulton-DeKalb Hospital Authority
  • Epidemiologist, Centers for Disease Control
  • Epidemiology (MPH, PhD), Emory University
  • Veterinary Medicine (DVM), Kansas State University
  • Animal Bioscience/Environmental Resource Management (B.S.), Penn State University

Key Leader Group

Head of MedicalWilliam O. Frank

  • Vice President, Retrophin Inc.
  • Vice President, Vital Therapies Inc.
  • Senior Medical Director and Vice President, Santarus Inc.
  • Senior Medical Director, Novartis
  • Director, Clinical Research & Development, Sandoz
  • Group Director, Clinical Development & Medical Affairs, Smith-Kline Beecham Pharmaceutical Corporation
  • MD, Temple University
  • BS in Chemistry and Biological Sciences, University of Pittsburgh

Key Leader Group

Regulatory AffairsCindy Fisher

  • Director, Regulatory Affairs, Vical Incorporated.
  • Principal Scientist, Structural Bioinformatics, Inc.
  • Postdoctoral Fellow, Scripps Research Institute
  • Postdoctoral Fellow, Agouron Institute
  • PhD in Physical Organic Chemistry, UC Irvine
  • BS in Chemistry, UCLA

Key Leader Group

Quality AssuranceJose Zapata

  • Sr. Director (QA), Histogen
  • Director Quality Assurance, Quality System, Conatus Pharma
  • Director (QA), Peregrine Pharmaceuticals Inc.
  • Director (QA-Renal division), OPKO (Formally Cytochroma)
  • Associate Director (QA), Immtech Pharmaceutical
  • Director (QA & Regulatory Affairs), Resource Optimization Innovation
  • Director (QA), Triad Pharmaceuticals
  • Quality Assurance Director (Fluid Air), PharmaPro Services
  • Manager (QA), Opportunity Medical
  • Quality & Regulatory (M.S.), Temple University – Lewis Katz School of Medicine
  • Biological Science (B.S.), DePaul University
TOP

COPYRIGHT ⓒ 2020 HELIXMITH Co., Ltd. ALL RIGHTS RESERVED.